Serum cytokine profile in stable patients with work8related chronic obstructive pulmonary disease and relationship to other inflammatory markers

The aim of this study was to investigate serum cytokine profile in stable patients with chronic obstructive pulmonary disease (COPD) caused by siliconcontaining dust exposure and to evaluate relationships between cytokines and some inflammatory biomarkers.

Methods. Patients (n = 234) with stable workrelated COPD were involved. To assess inflammation severity, we measured interleukins IL1β, IL4, IL6, IL8, tumor necrosis factor α (TNFα) in blood serum using immunoassay. Cytokine level was compared with inflammatory marker levels, such as Creactive protein (CRP), ferritin, erythrocyte sedimentation rate (ESR), blood leukocyte number, nitric oxide metabolites, immunoglobulins (IgG, IgA, IgM). Reparation of damaged airway epithelium was assessed by serum concentration of Clara cell protein (CC16) using immunoassay.

Results. There was no difference between cytokine and inflammatory marker levels in most patients with stable workrelated COPD and control subjects. This means that inflammation tin the airways was mild and only slightly depended on degree of bronchial obstruction. Systemic inflammation in COPD was confirmed by elevated CRP level (5.0 – 10.0 mg/L) found in a half of patients with workrelated COPD.

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD).Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2014). Availableat: htpp://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun 11. pdf. Global Initiative for Chronic Obstructive Lung Disease, Inc; 2014.

2. Chuchalin A.G., ed. Handbook on Respiratory Medicine. Moscow: GEOTAR'Media; 2007. V. 2 (in Russian).

3. Avdeev S.N. Definition of clinical phenotypes of chronic obstructive pulmonary disease as a novel approach to treatment. Terapevticheskiy arkhiv. 2011; 3 (83): 66–74 (in Russian).

4. Plyukhin A.E., Burmistrova T.B., Elovskaya L.T. Occupational diseases caused by exposure to industrial aerodols. In: Izmerov N.F., ed. Occupational Diseases: National Handbook. Moscow: GEOTAR'Media; 2011: 343–425 (in Russian).

5. Chuchalin A.G., Avdeev S.N., Aysanov Z.R. et al. Russian Respiratory Society. Federal clinical guidelines on diagnosis and management of chronic obstructive pulmonary disease. Pul'monologiya. 2014; 3: 15–36 (in Russian).

6. Murugan V., Peck M.J. Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease. Exp. Lung Res. 2009; 35 (6): 439–485.

7. Gilowska I. CXCL8 (interleukin 8) – the key inflammatory mediator in chronic obstructive pulmonary disease? Postepy. Hig. Med. Dosw. 2014; 68: 842–850.

8. Sichelstiel A., Yadava K., Trompette A. et al. Targeting IL1β and IL17A driven inflammation during influenza induced exacerbations of chronic lung inflammation PLoS One. 2014; 9 (2): e98440. DOI: 10.1371 / journal.pone. 0098440. eCollection 2014.

9. Du Y.J., Yang C.J., Li B. et al. Association of proinflammatory cytokines, cortisol and depression in patients with chronic obstructive pulmonary disease. Psychoneuroendo crinology. 2014; 46: 141–152. DOI: 10.1016 / j.psyneuen. 2014.04.020.

10. Xia J., Zhao J., Shang J. et al. Increased IL33 expression in chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015; 308 (7): L619–L627. DOI: 10.1152, ajplung.00305.2014.

11. Caramori G., Adcock I.M., DiStefano A., Chung K.F. Cytokine inhibition in the treatment of COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 397–412. DOI:

12. 2147, COPD. S42544. eCollection 2014.

13. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. Updated 2011. www.ginasthma.org

14. Chuchalin A.G., Aysanov Z.R., Belevskiy A. et al. Federal guidelines on diagnosis and treatment of bronchial asthma. Pulmonologiya. 2014; 2: 11–32 (in Russian).

15. Organov R.G., ed. National recommendations on diagnosis and treatment of metabolic syndrome. Moscow: Solitseya' Poligra; 2010: 278–316 (in Russian).

16. Chuchalin A.G., Aysanov Z.R., Chikina S.Yu. et al. Federal clinical guidelines of Russian Respiratory Society on spirometry. Pul'monologiya. 2014; 6: 11–23 (in Russian).

17. Men'shikov V.V., ed. Clinical Laboratory Testing Techniques. A Reference Book. Moscow: Labora. 2008; Vol. 1: 62 (in Russian).

18. Men'shikov V.V., ed. Clinical laboratory testing techniques.Immunological tests. A reference book. Moscow: Labora; 2009, V. 2: 43–47 (in Russian).

19. Shmelev E.I. Antiinflammatory treatment with fenspirid in patients with chronic obstructive pulmonary disease. Consilium Medicum: Bolezni organov dykhaniya. 2008; 12: 35–39 (in Russian).

20. Levitskiy V.A. Clinical, endoscopic and pathological examinations of large bronchi in chronic bronchitis, bronchial asthma and lung carcinoma: Diss. Tomsk; 2004 (in Russian).

21. Rawlins E.L., Okubo T., Xue Y. et al. The role of Scgb1a1+ Claracells in the longterm maintenance and repair of lung airway, but not alveolar, epithelium. Cell. Stem. Cell. 2009; 4 (6): 525–534.

22. Kishkun A.A. Handbook on Laboratory Diagnostic Methods. Moscow: GEOTAR'Media; 2009: 403–405 (in Russian).